Zacks Investment Research
07 Aug 2026, 16:50 UTC · 1h ago
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
07 Aug 2026, 16:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
BioMarin reported Q2 2026 adjusted earnings of $1.20 per share and total revenues of $989.7 million, both exceeding Zacks Consensus Estimates. — Beating both top and bottom-line estimates typically triggers positive short-term price action.
+0.60BioMarin management raised key elements of its 2026 financial guidance. — Guidance raises signal confidence in future growth and often provide a sustained catalyst for stock price appreciation.
+0.50Voxzogo maintained a 90% U.S. patient retention rate through July despite the entry of a competing product into the market. — Strong retention in the face of new competition demonstrates a competitive moat and reduces risk of market share erosion.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
BioMarin's net product revenues grew 21% year-over-year, driven by Metabolic Conditions drugs and Voxzogo. — Strong organic and acquisition-led revenue growth confirms the company's scaling capabilities.
+0.30Vimizim revenues fell 10% to $194 million, missing the Zacks Consensus Estimate of $205.8 million. — While attributed to timing of government orders, a revenue miss in a specific product line is a negative signal.
-0.20Which stocks this story touches
Company beat earnings and revenue estimates, raised financial guidance, and saw a positive after-market stock reaction.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
53m ago
